Risk of fatal adverse events in VEGF-targeting cancer drugs
Added: Friday 30 March 2012
Cancer drugs that target the vascular endothelial growth factor (VEGF) receptor have been found to increase the risk of fatal side effects in cancer patients, but researchers point out that the overall rate of fatal adverse events is still low and the three drugs in the study have been shown to improve clinical outcomes compared to traditional therapies. Patients in the study had a variety of different cancers.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: